标题
CD133, Selectively Targeting the Root of Cancer
作者
关键词
-
出版物
Toxins
Volume 8, Issue 6, Pages 165
出版商
MDPI AG
发表日期
2016-05-30
DOI
10.3390/toxins8060165
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker
- (2016) Joerg U Schmohl et al. MOLECULAR THERAPY
- Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis
- (2015) G. Bertolini et al. CANCER RESEARCH
- Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis
- (2015) Bin Wu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody
- (2015) Lei Zhao et al. JOURNAL OF IMMUNOTHERAPY
- Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells
- (2015) K Pinz et al. LEUKEMIA
- HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
- (2015) Huimin Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells
- (2015) J. U. Schmohl et al. Targeted Oncology
- Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis
- (2015) Chen Zhong et al. TUMOR BIOLOGY
- Interleukin-15 in the treatment of cancer
- (2014) Thomas A Waldmann Expert Review of Clinical Immunology
- Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
- (2014) Saar Gill et al. IMMUNOLOGICAL REVIEWS
- Bispecific T-cell engagers for cancer immunotherapy
- (2014) Amelia M Huehls et al. IMMUNOLOGY AND CELL BIOLOGY
- Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer
- (2014) Jonathan S. Berek et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model
- (2014) Grzegorz Basak et al. ONCOLOGY REPORTS
- Identification of CD24 as a Cancer Stem Cell Marker in Human Nasopharyngeal Carcinoma
- (2014) Chun-Hung Yang et al. PLoS One
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures
- (2013) Junsong Chen et al. BMC CELL BIOLOGY
- Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells
- (2013) Daniel A. Vallera et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- HER2 and Breast Cancer Stem Cells: More than Meets the Eye
- (2013) H. Korkaya et al. CANCER RESEARCH
- Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133high cancer stem cells in vitro and in vivo
- (2013) Jianhua Huang et al. CLINICAL IMMUNOLOGY
- Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression
- (2013) Amy P.N. Skubitz et al. GYNECOLOGIC ONCOLOGY
- CD133 expression in circulating tumor cells from breast cancer patients: Potential role in resistance to chemotherapy
- (2013) Rosa Nadal et al. INTERNATIONAL JOURNAL OF CANCER
- CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer
- (2013) Suresh Kumar Swaminathan et al. JOURNAL OF CONTROLLED RELEASE
- Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
- (2013) Irène Baccelli et al. NATURE BIOTECHNOLOGY
- Developing Therapeutic Antibodies for Neurodegenerative Disease
- (2013) Y. Joy Yu et al. Neurotherapeutics
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma
- (2013) Nate N. Waldron et al. Targeted Oncology
- TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction
- (2013) V Tirino et al. Cell Death & Disease
- The stem cell marker prominin-1/CD133 interacts with vascular endothelial growth factor and potentiates its action
- (2012) Avner Adini et al. ANGIOGENESIS
- Lung Cancer Stem Cells as a Target for Therapy
- (2012) Elieser Gorelik et al. Anti-Cancer Agents in Medicinal Chemistry
- RNA aptamers targeting cancer stem cell marker CD133
- (2012) Sarah Shigdar et al. CANCER LETTERS
- CD133: holy of grail of neuro-oncology or promiscuous red-herring?
- (2012) L. K. Donovan et al. CELL PROLIFERATION
- CD133 as a target for colon cancer
- (2012) Veronica Catalano et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Epithelial Cell Adhesion Molecule Regulates Tumor Initiation and Tumorigenesis via Activating Reprogramming Factors and Epithelial-Mesenchymal Transition Gene Expression in Colon Cancer
- (2012) Cheng-Wei Lin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Detailed Mammosphere Assay Protocol for the Quantification of Breast Stem Cell Activity
- (2012) Frances L. Shaw et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges
- (2012) Philipp Grosse-Gehling et al. JOURNAL OF PATHOLOGY
- CXCR4-Positive Subset of Glioma Is Enriched for Cancer Stem Cells
- (2012) Xuesheng Zheng et al. ONCOLOGY RESEARCH
- Regulation of CD133 by HDAC6 Promotes β-Catenin Signaling to Suppress Cancer Cell Differentiation
- (2012) Anthony B. Mak et al. Cell Reports
- Identification and characterization of a novel scFv recognizing human and mouse CD133
- (2012) Suresh Kumar Swaminathan et al. Drug Delivery and Translational Research
- Immunotoxin targeting CD133+ breast carcinoma cells
- (2012) John R. Ohlfest et al. Drug Delivery and Translational Research
- Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies
- (2011) Sarah Shigdar et al. BRITISH JOURNAL OF HAEMATOLOGY
- Calcium-binding protein S100P and cancer: mechanisms and clinical relevance
- (2011) Hongfei Jiang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Inhibition of CD133+ Cells in Oral Cancer Cell Lines
- (2011) M. Damek-Poprawa et al. JOURNAL OF DENTAL RESEARCH
- Targeting Tumor-Initiating Cancer Cells with dCD133KDEL Shows Impressive Tumor Reductions in a Xenotransplant Model of Human Head and Neck Cancer
- (2011) N. N. Waldron et al. MOLECULAR CANCER THERAPEUTICS
- Unknown
- (2011) Ilya Ulasov et al. MOLECULAR MEDICINE
- MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells
- (2011) Moorthy P Ponnusamy et al. Journal of Ovarian Research
- Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals
- (2010) Erik W. Orava et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- The AC133 Epitope, but not the CD133 Protein, Is Lost upon Cancer Stem Cell Differentiation
- (2010) K. Kemper et al. CANCER RESEARCH
- CD44posCD49fhiCD133/2hi Defines Xenograft-Initiating Cells in Estrogen Receptor–Negative Breast Cancer
- (2010) Matthew J. Meyer et al. CANCER RESEARCH
- EpCAM in carcinogenesis: the good, the bad or the ugly
- (2010) B. T. F. van der Gun et al. CARCINOGENESIS
- Identification of a novel monoclonal antibody recognizing CD133
- (2010) Suresh Kumar Swaminathan et al. JOURNAL OF IMMUNOLOGICAL METHODS
- CD133 suppresses neuroblastoma cell differentiation via signal pathway modification
- (2010) H Takenobu et al. ONCOGENE
- The Emerging Role of EpCAM in Cancer and Stem Cell Signaling
- (2009) M. Munz et al. CANCER RESEARCH
- Targeting CD133 antigen in cancer
- (2009) Gabriella Ferrandina et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Macromolecular drug transport into the brain using targeted therapy
- (2009) Jacek Lichota et al. JOURNAL OF NEUROCHEMISTRY
- Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells
- (2009) K. S. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44
- (2009) Shigeo Takaishi et al. STEM CELLS
- CD133 as a Marker for Cancer Stem Cells: Progresses and Concerns
- (2009) Yaojiong Wu et al. STEM CELLS AND DEVELOPMENT
- Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas
- (2008) Heike Immervoll et al. BMC CANCER
- CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
- (2008) L M Smith et al. BRITISH JOURNAL OF CANCER
- CD133 expression is an independent prognostic marker for low survival in colorectal cancer
- (2008) D Horst et al. BRITISH JOURNAL OF CANCER
- CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer
- (2008) S Maeda et al. BRITISH JOURNAL OF CANCER
- Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
- (2008) S. Zhang et al. CANCER RESEARCH
- New Insights into the Cell Biology of Hematopoietic Progenitors by Studying Prominin-1 (CD133)
- (2008) Nicola Bauer et al. CELLS TISSUES ORGANS
- CD44 is of Functional Importance for Colorectal Cancer Stem Cells
- (2008) L. Du et al. CLINICAL CANCER RESEARCH
- Recent advances in cancer stem cells
- (2008) Robert W Cho et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Cancer Stem Cells: A Step Toward the Cure
- (2008) Bruce M. Boman et al. JOURNAL OF CLINICAL ONCOLOGY
- IL-15 trans-presentation promotes human NK cell development and differentiation in vivo
- (2008) Nicholas D. Huntington et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Stem Cell Marker CD133 (Prominin-1) Is Expressed in Various Human Glandular Epithelia
- (2008) Jana Karbanová et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation
- (2008) Liqin Zhu et al. NATURE
- Expression profiling of CD133+and CD133-epithelial cells from human prostate
- (2008) Christopher J. Shepherd et al. PROSTATE
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
- The Stem Cell-Associated Antigen CD133 (Prominin-1) Is a Molecular Therapeutic Target for Metastatic Melanoma
- (2008) Germana Rappa et al. STEM CELLS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started